These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 23598698)

  • 21. Enhanced non invasive trans-tympanic delivery of ciprofloxacin through encapsulation into nano-spanlastic vesicles: Fabrication, in-vitro characterization, and comparative ex-vivo permeation studies.
    Al-Mahallawi AM; Khowessah OM; Shoukri RA
    Int J Pharm; 2017 Apr; 522(1-2):157-164. PubMed ID: 28279741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ciprofloxacin for the treatment of chronic ear disease.
    Piccirillo JF; Parnes SM
    Laryngoscope; 1989 May; 99(5):510-3. PubMed ID: 2651829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nano-transfersomal ciprofloxacin loaded vesicles for non-invasive trans-tympanic ototopical delivery: in-vitro optimization, ex-vivo permeation studies, and in-vivo assessment.
    Al-Mahallawi AM; Khowessah OM; Shoukri RA
    Int J Pharm; 2014 Sep; 472(1-2):304-14. PubMed ID: 24971692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
    Hansen CR; Pressler T; Høiby N
    J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Zymar (Gatifloxacin 0.3%) shows excellent Gram-negative activity against Serratia marcescens and Pseudomonas aeruginosa in a New Zealand White rabbit keratitis model.
    Mah FS; Romanowski EG; Kowalski RP; Yates KA; Gordon YJ
    Cornea; 2007 Jun; 26(5):585-8. PubMed ID: 17525656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emergence of ciprofloxacin-resistant pseudomonas in chronic suppurative otitis media.
    Jang CH; Park SY
    Clin Otolaryngol Allied Sci; 2004 Aug; 29(4):321-3. PubMed ID: 15270816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Formulation and evaluation of controlled release antibiotic biodegradable implants for post operative site delivery.
    Mathur V; Mudnaik R; Barde L; Roy A; Shivhare U; Bhusari K
    Acta Pharm; 2010 Mar; 60(1):111-7. PubMed ID: 20228045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Gyrase inhibitor in the local treatment of the chronically infected middle ear following surgery].
    Ganz H
    HNO; 1986 Dec; 34(12):511-4. PubMed ID: 3028994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ciprofloxacin iontophoresis for aminoglycoside-resistant pseudomonal keratitis.
    Hobden JA; Reidy JJ; O'Callaghan RJ; Insler MS; Hill JM
    Invest Ophthalmol Vis Sci; 1990 Oct; 31(10):1940-4. PubMed ID: 2210988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel poly-DL-lactide-polycaprolactone copolymer based flexible drug delivery system for sustained release of ciprofloxacin.
    Waknis V; Jonnalagadda S
    Drug Deliv; 2011 May; 18(4):236-45. PubMed ID: 21189060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of ciprofloxacin-dexamethasone on myringotomy wound healing.
    Hebda PA; Yuksel S; Dohar JE
    Laryngoscope; 2007 Mar; 117(3):522-8. PubMed ID: 17334316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form.
    Schuck EL; Dalhoff A; Stass H; Derendorf H
    Infection; 2005 Dec; 33 Suppl 2():22-8. PubMed ID: 16518708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo release of ciprofloxacin from osteoconductive bone defect filler.
    Mäkinen TJ; Veiranto M; Lankinen P; Moritz N; Jalava J; Törmälä P; Aro HT
    J Antimicrob Chemother; 2005 Dec; 56(6):1063-8. PubMed ID: 16234335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Current therapeutical management, new antibiotics and treatment of Pseudomonas aeruginosa in bacterial ENT-infections].
    Elies W
    Laryngorhinootologie; 2002 Jan; 81(1):40-5. PubMed ID: 11845401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of experimental Pseudomonas aeruginosa keratitis.
    Guzek JP; Chacko D; Kettering JD; Wessels IF; Aprecio RM
    Cornea; 1994 Nov; 13(6):500-4. PubMed ID: 7842708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pseudomonas aeruginosa infection due to acupunctural ear stapling.
    Morgan AE
    Am J Infect Control; 2008 Oct; 36(8):602. PubMed ID: 18926318
    [No Abstract]   [Full Text] [Related]  

  • 37. Transtympanic versus sustained-release administration of gentamicin: kinetics, morphology, and function.
    Hoffer ME; Allen K; Kopke RD; Weisskopf P; Gottshall K; Wester D
    Laryngoscope; 2001 Aug; 111(8):1343-57. PubMed ID: 11568567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Collagen bilayer dressing with ciprofloxacin, an effective system for infected wound healing.
    Sripriya R; Kumar MS; Ahmed MR; Sehgal PK
    J Biomater Sci Polym Ed; 2007; 18(3):335-51. PubMed ID: 17471769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of ciprofloxacin and dexamethasone in the guinea pig middle ear.
    Lemke LE; McGee DH; Prieskorn DM; Wall GM; Dolan DF; Altschuler RA; Miller JM
    Arch Otolaryngol Head Neck Surg; 2009 Jun; 135(6):575-80. PubMed ID: 19528406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. OTO-201: nonclinical assessment of a sustained-release ciprofloxacin hydrogel for the treatment of otitis media.
    Wang X; Fernandez R; Tsivkovskaia N; Harrop-Jones A; Hou HJ; Dellamary L; Dolan DF; Altschuler RA; LeBel C; Piu F
    Otol Neurotol; 2014 Mar; 35(3):459-69. PubMed ID: 24518407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.